MASTERINVEST Kapitalanlage GmbH Invests $1.92 Million in Stryker Corporation $SYK

MASTERINVEST Kapitalanlage GmbH acquired a new position in shares of Stryker Corporation (NYSE:SYK) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,855 shares of the medical technology company’s stock, valued at approximately $1,921,000.

A number of other hedge funds have also bought and sold shares of the company. Two Point Capital Management Inc. acquired a new position in shares of Stryker during the second quarter valued at about $7,281,000. Alecta Tjanstepension Omsesidigt increased its position in Stryker by 82.0% in the 2nd quarter. Alecta Tjanstepension Omsesidigt now owns 458,300 shares of the medical technology company’s stock valued at $181,235,000 after buying an additional 206,500 shares in the last quarter. SVB Wealth LLC bought a new stake in Stryker in the 2nd quarter valued at about $4,785,000. AXQ Capital LP acquired a new position in Stryker during the 2nd quarter worth approximately $567,000. Finally, United Services Automobile Association bought a new position in Stryker in the first quarter worth approximately $2,857,000. Institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 276,173 shares of Stryker stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the sale, the director directly owned 2,702,108 shares in the company, valued at approximately $954,600,714.24. This trade represents a 9.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Preston Wendell Wells sold 165 shares of the company’s stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $365.88, for a total value of $60,370.20. Following the completion of the transaction, the chief financial officer owned 6,694 shares of the company’s stock, valued at $2,449,200.72. This trade represents a 2.41% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 522,118 shares of company stock worth $185,381,932. 5.90% of the stock is owned by company insiders.

Stryker Stock Performance

NYSE SYK opened at $353.99 on Friday. The company has a fifty day moving average price of $366.81 and a 200-day moving average price of $378.46. The firm has a market cap of $135.37 billion, a price-to-earnings ratio of 46.52, a PEG ratio of 2.51 and a beta of 0.89. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.85 and a quick ratio of 1.13. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $406.19.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, topping the consensus estimate of $3.13 by $0.06. The business had revenue of $6.06 billion for the quarter, compared to analysts’ expectations of $6.04 billion. Stryker had a net margin of 12.07% and a return on equity of 24.07%. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the previous year, the company earned $2.87 earnings per share. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. As a group, equities research analysts predict that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Wednesday, December 31st will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, December 31st. This is a positive change from Stryker’s previous quarterly dividend of $0.84. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. Stryker’s dividend payout ratio (DPR) is 44.15%.

Analyst Upgrades and Downgrades

Several research firms have recently commented on SYK. Wall Street Zen downgraded Stryker from a “buy” rating to a “hold” rating in a report on Saturday. Rothschild & Co Redburn assumed coverage on shares of Stryker in a research note on Thursday, September 18th. They set a “neutral” rating and a $420.00 price target for the company. Citigroup lowered their price objective on shares of Stryker from $455.00 to $420.00 and set a “buy” rating on the stock in a report on Thursday. Needham & Company LLC reiterated a “buy” rating and set a $448.00 price objective on shares of Stryker in a report on Friday, November 14th. Finally, Sanford C. Bernstein reissued an “outperform” rating on shares of Stryker in a research report on Monday, November 3rd. Twelve analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $431.83.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.